Lysosomal membrane permeabilization enhances the anticancer effects of POLR1 (RNA polymerase I) transcription

Lucille Ferret1,2,3, Jonathan G Pol1,2, Allan Sauvat1,2

  • 1Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université de Paris Cité, Équipe labellisée par la Ligue contre le Cancer, Institut Universitaire de France, Paris, France.

Autophagy
|June 18, 2025
PubMed

Insights

Lysosomes can cause resistance to cancer drugs like CX-3543 by sequestering them. Targeting lysosomes with chloroquine or light releases the drug, enhancing its cancer-killing effects and reducing tumor growth.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Lysosomes contribute to drug resistance via sequestration and stress pathway activation.
  • The role of lysosomes in resistance to transcription inhibitors is largely unknown.
  • This study focuses on RNA polymerase I (POLR1) inhibitors CX-3543 and CX-5461.

Purpose of the Study:

  • To investigate the role of lysosomes in cellular responses to POLR1 inhibitors.
  • To explore mechanisms of drug resistance and potential strategies to overcome it.

Main Methods:

  • Investigated drug accumulation and lysosomal membrane permeabilization (LMP) of CX-3543.
  • Assessed the impact of TFEB and autophagy pathways on CX-3543 sensitivity.
  • Utilized chloroquine derivatives and blue light to induce LMP and drug release.
  • Evaluated combination therapies in vitro and in vivo (fibrosarcoma mouse model).

Main Results:

  • CX-3543 unexpectedly accumulated in lysosomes, causing LMP and activating TFEB and autophagy.
  • Disrupting TFEB or autophagy increased sensitivity to CX-3543, indicating a cytoprotective role.
  • Targeting lysosomal membranes enhanced CX-3543's anti-transcription and cell death effects.
  • Combination therapy (CX-3543 + DC661) reduced fibrosarcoma growth more effectively than single agents.

Conclusions:

  • Lysosomes play an unexpected role in resistance to POLR1 inhibitors.
  • TFEB and autophagy pathways confer cytoprotection against CX-3543.
  • Targeting lysosomal membranes is a viable strategy to overcome resistance to POLR1 inhibitors.